Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,319.42 +12.41 (+0.23%) Dow
39,405.02 -266.02 (-0.67%) Nasdaq
16,935.55 +134.01 (+0.80%) Bitcoin USD
68,010.80 -2,391.09 (-3.40%) CMC Crypto 200
1,476.71 -25.95 (-1.73%)
NVO Jan 2026 85.000 put
| Previous close | 3.2000 |
| Open | 3.2000 |
| Bid | 2.3500 |
| Ask | 3.1500 |
| Strike | 85.00 |
| Expiry date | 2026-01-16 |
| Day's range | 3.2000 - 3.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 27 |
ZacksWhy This 1 Medical Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
BenzingaNovo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to meet on May 24 to review Novo Nordisk A/S’s (NYSE:NVO) application seeking approval for a once-weekly insulin icodec. In December 2023, the FDA said that data submitted by Novo Nordisk during the regulatory review is considered to constitute a major amendment to the Biologics License Application (BLA) for insulin icodec. Therefore, the regulatory review is extended by three months to provide time for a full submissio
Barrons.comHims & Hers Is Selling Copycat Weight-Loss Drugs. Here’s How.
A plan by Hims & Hers Health to sell legal copies of Novo Nordisk weight loss drug Wegovy is drawing pushback from the industry, and bringing new attention to an area of concern for public-health officials. Enormous demand has created shortages of Novo’s Wegovy, as well as a competing weight loss injection from Eli Lilly called Zepbound. Both companies are spending billions of dollars to increase their manufacturing capacity, but the availability of the medicines is limited in the U.S., according to the Food and Drug Administration.
